This Billboard Japan interview explores how getting closer to fans overseas shifted their mindset in some ways and left other ...
Bristol-Myers Squibb raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus. Click here to find out why BMY is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback